{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:09:03Z","timestamp":1791976143309,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40262-020-00872-4","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T22:02:27Z","timestamp":1582927347000},"page":"849-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-1130","authenticated-orcid":false,"given":"Dominique","family":"Lev\u00eaque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanti","family":"Natarajan-Am\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"issue":"5682","key":"872_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399\u2013401.","journal-title":"Science"},{"issue":"9","key":"872_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2135","volume":"5","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov. 2006;5(9):717\u20138.","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"872_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Dasatinib: a review in chronic myeloid leukaemia and Ph\u2009+\u2009acute lymphoblastic leukaemia. Drugs. 2017;77(1):85\u201396.","journal-title":"Drugs."},{"issue":"24","key":"872_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531\u201341.","journal-title":"N Engl J Med"},{"issue":"20","key":"872_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"872_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"7","key":"872_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cncr.24155","volume":"115","author":"HJ Khoury","year":"2009","unstructured":"Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009;115(7):1381\u201394.","journal-title":"Cancer"},{"key":"872_CR8","doi-asserted-by":"publisher","unstructured":"Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. Epub 16 Jan 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5868.","DOI":"10.1001\/jamaoncol.2019.5868"},{"issue":"2","key":"872_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ejh.13247","volume":"103","author":"E Lennmyr","year":"2019","unstructured":"Lennmyr E, Karlsson K, Ahlberg L, Garelius H, Huleg\u00e5rdh E, Izarra AS, et al. Survival in adult acute lymphoblastic leukaemia (ALL): a report from the Swedish ALL Registry. Eur J Haematol. 2019;103(2):88\u201398.","journal-title":"Eur J Haematol"},{"issue":"22","key":"872_CR10","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of children\u2019s oncology group trial AALL0622. J Clin Oncol. 2018;36(22):2306\u201314.","journal-title":"J Clin Oncol"},{"key":"872_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50\u00a0mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67\u201375.","journal-title":"Cancer"},{"issue":"19","key":"872_CR12","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204\u201312.","journal-title":"J Clin Oncol"},{"key":"872_CR13","doi-asserted-by":"crossref","unstructured":"Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36(13):1330-8.","DOI":"10.1200\/JCO.2017.75.9597"},{"issue":"9","key":"872_CR14","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1124\/dmd.107.020255","volume":"36","author":"L Wang","year":"2008","unstructured":"Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008;36(9):1828\u201339.","journal-title":"Drug Metab Dispos"},{"key":"872_CR15","doi-asserted-by":"crossref","unstructured":"Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways [published erratum appears in Drug Metab Dispos. 2009;37(10):2118]. Drug Metab Dispos. 2009;37(6):1242\u201350.","DOI":"10.1124\/dmd.108.025932"},{"issue":"3","key":"872_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1124\/jpet.109.154781","volume":"330","author":"Y Chen","year":"2009","unstructured":"Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther. 2009;330(3):956\u201363.","journal-title":"J Pharmacol Exp Ther"},{"key":"872_CR17","doi-asserted-by":"crossref","unstructured":"D\u2019Cunha R, Bae S, Murry DJ, An G.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos. 2016;37(7):397\u2013408.","DOI":"10.1002\/bdd.2022"},{"issue":"5","key":"872_CR18","doi-asserted-by":"publisher","first-page":"e27618","DOI":"10.1002\/pbc.27618","volume":"66","author":"LB Ramsey","year":"2019","unstructured":"Ramsey LB, Mizuno T, Vinks AA, O\u2019Brien MM. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatr Blood Cancer. 2019;66(5):e27618.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"872_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.xphs.2018.11.005","volume":"108","author":"S Vaidhyanathan","year":"2019","unstructured":"Vaidhyanathan S, Wang X, Crison J, Varia S, Gao JZH, Saxena A, Good D. Bioequivalence comparison of pediatric dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharm Sci. 2019;108(1):741\u20139.","journal-title":"J Pharm Sci"},{"issue":"7","key":"872_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"LJ Christopher","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36(7):1357\u201364.","journal-title":"Drug Metab Dispos"},{"key":"872_CR21","unstructured":"Sprycel, INN-dasatinib\u2014European Medicines Agency. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/sprycel-epar-product-information_fr.pdf. Accessed 19 Oct 2019."},{"issue":"4","key":"872_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","volume":"112","author":"K Porkka","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lund\u00e1n T, Rimpil\u00e4inen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005\u201312.","journal-title":"Blood"},{"issue":"7","key":"872_CR23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3109\/10428194.2012.745933","volume":"54","author":"HS Zhou","year":"2013","unstructured":"Zhou HS, Dai M, Wei Y, Wang Q, Xu N, Yin C, Meng F. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid. Leuk Lymphoma. 2013;54(7):1557\u20139.","journal-title":"Leuk Lymphoma"},{"key":"872_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/2193-1801-3-177","volume":"3","author":"T Kondo","year":"2014","unstructured":"Kondo T, Tasaka T, Matsumoto K, Matsumoto R, Koresawa L, Sano F, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib. Springerplus. 2014;3:177.","journal-title":"Springerplus."},{"issue":"11","key":"872_CR25","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","volume":"19","author":"A Broniscer","year":"2013","unstructured":"Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013;19(11):3050\u20138.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"872_CR26","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009;15(19):6232\u201340.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"872_CR27","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s10637-011-9732-3","volume":"30","author":"A Argiris","year":"2012","unstructured":"Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, et al. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs. 2012;30(4):1575\u201384.","journal-title":"Invest New Drugs"},{"issue":"7","key":"872_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","volume":"29","author":"R Aplenc","year":"2011","unstructured":"Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children\u2019s oncology group phase I consortium. J Clin Oncol. 2011;29(7):839\u201344.","journal-title":"J Clin Oncol"},{"issue":"19","key":"872_CR29","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","volume":"31","author":"CM Zwaan","year":"2013","unstructured":"Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31(19):2460\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"872_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12185-009-0326-1","volume":"89","author":"DW Kim","year":"2009","unstructured":"Kim DW, Goh YT, Hsiao HH, Caguioa PB, Kim D, Kim WS, et al. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol. 2009;89(5):664\u201372.","journal-title":"Int J Hematol"},{"issue":"11","key":"872_CR31","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/j.1349-7006.2011.02041.x","volume":"102","author":"S Takahashi","year":"2011","unstructured":"Takahashi S, Miyazaki M, Okamoto I, Ito Y, Ueda K, Seriu T, et al. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci. 2011;102(11):2058\u201364.","journal-title":"Cancer Sci"},{"issue":"6","key":"872_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","volume":"49","author":"T Eley","year":"2009","unstructured":"Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"872_CR33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","volume":"69","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999\u20131004.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"872_CR34","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1208\/s12248-014-9673-9","volume":"16","author":"MR Yago","year":"2014","unstructured":"Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358\u201365.","journal-title":"AAPS J"},{"issue":"6","key":"872_CR35","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/cncr.24927","volume":"116","author":"FM Johnson","year":"2010","unstructured":"Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010;116(6):1582\u201391.","journal-title":"Cancer"},{"issue":"7","key":"872_CR36","doi-asserted-by":"publisher","first-page":"e27035","DOI":"10.1002\/pbc.27035","volume":"65","author":"A Broniscer","year":"2018","unstructured":"Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, et al. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2018;65(7):e27035.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"872_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/dmd.112.049114","volume":"41","author":"J Mao","year":"2013","unstructured":"Mao J, Johnson TR, Shen Z, Yamazaki S. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013;41(2):343\u201352.","journal-title":"Drug Metab Dispos"},{"key":"872_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4155\/ipk-2016-0022","volume":"2","author":"D Lev\u00eaque","year":"2017","unstructured":"Lev\u00eaque D, Becker G, Toussaint E, Fornecker LM, Paillard C. Clinical pharmacokinetics of methotrexate in oncology. Int J Pharmacokinet. 2017;2:137\u201347.","journal-title":"Int J Pharmacokinet."},{"issue":"5","key":"872_CR39","first-page":"85","volume":"10","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Clin Pharmacol. 2013;10(5):85\u201397.","journal-title":"Clin Pharmacol."},{"key":"872_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-8722-5-23","volume":"5","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Scott SA, Niioka T, Sawada K. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. J Hematol Oncol. 2012;5:23.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"872_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","volume":"72","author":"Y Ishida","year":"2016","unstructured":"Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K, et al. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol. 2016;72(2):185\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"872_CR42","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s10147-018-1300-9","volume":"23","author":"S Mizuta","year":"2018","unstructured":"Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, et al. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018;23(5):980\u20138.","journal-title":"Int J Clin Oncol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-020-00872-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T19:53:57Z","timestamp":1614455637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-020-00872-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00872-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"29 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dominique Lev\u00eaque, Guillaume Becker, Karin Bilger, and Shanti Natarajan-Am\u00e9 have no conflicts of interest to declare in relation to the subject matter. No writing assistance was utilised in the production of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}